Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Retained Earnings (2020 - 2025)

Candel Therapeutics' Retained Earnings history spans 4 years, with the latest figure at -$137.0 million for Q4 2023.

  • On a quarterly basis, Retained Earnings fell 38.29% to -$137.0 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$137.0 million, a 38.29% decrease, with the full-year FY2023 number at -$137.0 million, down 38.29% from a year prior.
  • Retained Earnings hit -$137.0 million in Q4 2023 for Candel Therapeutics, down from -$125.9 million in the prior quarter.
  • Over the last five years, Retained Earnings for CADL hit a ceiling of -$44.2 million in Q4 2020 and a floor of -$137.0 million in Q4 2023.
  • Historically, Retained Earnings has averaged -$93.3 million across 4 years, with a median of -$89.7 million in 2022.
  • Biggest five-year swings in Retained Earnings: tumbled 81.78% in 2021 and later fell 14.79% in 2022.
  • Tracing CADL's Retained Earnings over 4 years: stood at -$44.2 million in 2020, then tumbled by 81.78% to -$80.3 million in 2021, then decreased by 23.41% to -$99.1 million in 2022, then crashed by 38.29% to -$137.0 million in 2023.
  • Business Quant data shows Retained Earnings for CADL at -$137.0 million in Q4 2023, -$125.9 million in Q3 2023, and -$117.5 million in Q2 2023.